Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

In this decade a “bloom” of novel therapies has been observed for non-small cell lung cancer. We have new tools for the diagnosis of lung cancer and also we can re-biospy easier than before in different lesions and obtain tissue samples in order to investigate whether a patient can receive new targe...

Full description

Bibliographic Details
Main Authors: Paul Zarogoulidis, Evaggelia Athanasiou, Theodora Tsiouda, Dimitrios Hatzibougias, Haidong Huang, Chong Bai, Georgia Trakada, Lemonia Veletza, Anastasios Kallianos, Christoforos Kosmidis, Nikolaos Barbetakis, Dimitrios Paliouras, Aggeliki Rapti, Dimitrios Drougas, Wolfgang Hohenforst-Schmidt
Format: Article
Language:English
Published: Elsevier 2017-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Adenocarcinoma
Lung cancer
Immunotherapy
Nivolumab
Pembrolizumab
Programmed death-ligand
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007117302733

Internet

http://www.sciencedirect.com/science/article/pii/S2213007117302733

Similar Items